# A Randomized Phase II Study of Stereotactic Ablative Body Radiotherapy for Metastases to the Lung (TROG 13.01 SAFRON II)

> **NCT01965223** · NA · COMPLETED · sponsor: **Trans Tasman Radiation Oncology Group** · enrollment: 90 (actual)

## Conditions studied

- Cancer
- Metastases to the Lung

## Interventions

- **RADIATION:** Multi-fraction SABR
- **RADIATION:** Single Fraction SABR

## Key facts

- **NCT ID:** NCT01965223
- **Lead sponsor:** Trans Tasman Radiation Oncology Group
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-04
- **Primary completion:** 2020-07-27
- **Final completion:** 2020-07-27
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2020-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01965223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01965223, "A Randomized Phase II Study of Stereotactic Ablative Body Radiotherapy for Metastases to the Lung (TROG 13.01 SAFRON II)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01965223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*